Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer
Cancer Research · 2026-05-22
Abstract CT306: Phase 1 first-in-human multicenter open-label study of ZW191, a folate receptor α (FRα)-targeting antibody-drug conjugate (ADC), in patients with advanced solid tumors: Part 1 dose-escalation results
Cancer Research · 2026-04-17
Serum Extracellular Vesicle Protein Signatures Associated with Early-Stage High-Grade Serous Ovarian Carcinoma
Cells · 2026-04-16
Abstract 6529: Vaginal microbiome dynamics and clinical outcomes in cervical cancer patients undergoing radiotherapy
Cancer Research · 2026-04-03
HO-3867 reprograms the tumor microenvironment through extracellular vesicle regulation in ovarian cancer
Academia oncology. · 2026-02-12
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix
Journal for ImmunoTherapy of Cancer · 2026-02-01 · 1 citations
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201
Future Oncology · 2025-12-12 · 1 citations
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)
Journal of Clinical Oncology · 2025-12-12 · 7 citations
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma
Clinical Cancer Research · 2025-12-11 · 2 citations
Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
2025-11-25
Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
2025-11-25
A PHASE 3, OPEN-LABEL RANDOMIZED TRIAL TO COMPARE RINATABART SESUTECAN VERSUS INVESTIGATOR'S CHOICE OF CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER: RAINFOL™-02 (ENGOT-OV86/GOG-3107)
International Journal of Gynecological Cancer · 2025-11-01 · 1 citations
S63 Metabolic profiling of peripheral blood and tissue specific immune alterations in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)
2025-11-01
FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN’S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC)
International Journal of Gynecological Cancer · 2025-11-01
546 Sarilumab as a potential mitigator of ubamatamab (MUC16×CD3)-induced cytokine release syndrome (CRS) in patients with advanced ovarian cancer (OC) or endometrial cancer (EC)
Regular and Young Investigator Award Abstracts · 2025-11-01
Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer
Journal of Clinical Oncology · 2025-10-31
Abstract B013: Cyclin E1 Positive Protein Status is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer: Part 2 of the DENALI Study (GOG-3066)
Molecular Cancer Therapeutics · 2025-10-22
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study
Annals of Oncology · 2025-10-18 · 3 citations
Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
Journal of Clinical Oncology · 2025-10-13
Assessment of probiotic and prebiotic use in gynecologic cancer patients: a systematic review
American Journal of Obstetrics and Gynecology · 2025-10-08 · 2 citations